Metastatic Prostate Cancer Involving the Sphenoid Sinus and Mandible

Prostate cancer is the third most leading cause of cancer in men in the United States. Although expected metastatic spread to bone, liver, and lymph nodes are often monitored, there are other rare presentations that can occur. This case report demonstrates a rare presentation of prostate cancer spreading to the paranasal sinuses and orbit. Not only did this case have an atypical presentation mimicking infection, the diagnosis was also only achieved through pathological evaluation after an endoscopic examination and biopsy. This case demonstrates the importance of a low threshold for endoscopic examinations in uncertain sinonasal presentations, and consistent biopsies when performing endoscopic examinations.

Download Full-text

Cutaneous Metastasis of Prostate Adenocarcinoma: A Rare Presentation of a Common Disease

Journal of Investigative Medicine High Impact Case Reports ◽

10.1177/2324709621990769 ◽

2021 ◽

Vol 9 ◽

pp. 232470962199076

Author(s):

Alexander Dills ◽

Okechukwu Obi ◽

Kevin Bustos ◽

Jesse Jiang ◽

Shweta Gupta

Keyword(s):

Prostate Cancer ◽

Serine Proteases ◽

Cancer Genetics ◽

Performance Status ◽

Distant Metastases ◽

The United States ◽

Cutaneous Metastasis ◽

Common Disease ◽

Cutaneous Metastases ◽

Rare Presentation

Prostate cancer is the most common cancer affecting men in the United States and the second greatest cause of cancer-related death. Metastases usually occur to bone followed by distant lymph nodes and then viscera. Cutaneous metastases are extremely rare. Their presence indicates advanced disease and a poor prognosis. As they are highly variable in appearance and may mimic a more benign process, biopsy is essential for identification. Serine proteases, particularly human tissue kallikreins, may play an important role in promoting metastasis and facilitate infiltration of the skin. Individual cancer genetics may predispose to more aggressive cancer and thus earlier and more distant metastases. In this article, we report our case of a 67-year-old man with a 4-year history of castrate-resistant prostate cancer with cutaneous metastases confirmed by histology. Despite multiple lines of systemic therapy, the patient suffered progressive disease with worsening performance status and was enrolled in hospice.

Download Full-text

Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer

Clinical Medicine Insights Oncology ◽

10.4137/cmo.s4477 ◽

2010 ◽

Vol 4 ◽

pp. CMO.S4477 ◽

Cited By ~ 3

Author(s):

A.I. Ntekim ◽

A. Ajekigbe

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Hemorrhagic Cystitis ◽

The Third ◽

Hormone Refractory

A case is reported in which docetaxel was used to treat a patient with hormone refractory metastatic prostate cancer. The treatment was terminated at the third course of docetaxel following the development of hemorrhagic cystitis. This reaction was unexpected, as it is not a known reaction to docetaxel. Hemorrhagic cystitis has been associated with cyclophosphamide, where the metabolite acrolein has been implicated. The mechanism of this reaction from docetaxel is not yet known.

Download Full-text

Rare Paravertebral and Skull Base Metastases in Prostate Cancer

Case Reports in Oncology ◽

10.1159/000452327 ◽

2016 ◽

Vol 9 (3) ◽

pp. 738-746 ◽

Cited By ~ 2

Author(s):

Gbeminiyi Samuel ◽

Amir Isbell ◽

Onyekachi Ogbonna ◽

Hasan Iftikhar ◽

Susmita Sakruti ◽

...

Keyword(s):

Prostate Cancer ◽

United States ◽

Metastatic Prostate Cancer ◽

Clinical Presentation ◽

The United States ◽

Unique Case ◽

Skull Base Metastases ◽

The Right ◽

Upper Mediastinum ◽

Paravertebral Mass

Prostate cancer is the most commonly diagnosed visceral cancer in the United States. A majority of cases exhibit an insidious course and nonaggressive tumor behavior. Prostate cancer can manifest as lesions which remain localized, regionally invading or metastasize to lymph nodes, bones, and lungs. Here, we report a unique case of metastatic prostate cancer to the right upper mediastinum, presenting as a paravertebral mass within 2 years of initial tissue diagnosis. Paravertebral spread has not been described for prostate cancer, and herein, we discuss the clinical presentation, diagnostic workup, and possible therapeutic options available in light of the literature.

Download Full-text

Patterns of second-line chemotherapy for metastatic prostate cancer in the United States.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.5_suppl.169 ◽

2012 ◽

Vol 30 (5_suppl) ◽

pp. 169-169

Author(s):

Hongwei Wang ◽

Laura Liao ◽

Eliot Obi-Tabot ◽

Robert Sands ◽

Mathieu Rose ◽

...

Keyword(s):

Prostate Cancer ◽

Healthcare Costs ◽

Metastatic Prostate Cancer ◽

Hospital Admissions ◽

Treatment Options ◽

Patient Characteristics ◽

The United States ◽

Geographic Region ◽

Treatment Groups ◽

Comorbidity Burden

169 Background: Patients with prostate cancer progressing from 1st line (1L) docetaxel had limited treatment options available. This study is to evaluate patterns of 2nd line (2L) chemotherapy in US managed care between 2004 and 2010. Methods: Patients with metastatic prostate cancer (mPC) and treated with docetaxel as 1L chemotherapy after July 1, 2004 were ascertained from the OptumInsight database. We evaluated type and timing of chemotherapy and relationships between patient characteristics, physician specialty, healthcare costs and geographic region 6 months prior to 1L docetaxel and choice of 2L chemotherapy. Results: Patients (n=1,173) were on average 71 years old at the onset of 1L docetaxel. During a mean follow-up period of 18 months, 38% patients received 2L treatment. Out of the patients received 2L therapy, 32% received mitoxantrone (MITO), 24% with docetaxel rechallenge (RECH), 14% carboplatin (CARB), and 12% paclitaxel (PAC), plus 11% on combo therapy. An examination of the 2L treatment groups showed that during the 6 months prior to 1L docetaxel, the RECH group (n=101) was older (73yrs), had fewer hospital admissions (12%), lower comorbidity burden (Charlson Comorbidity Index (CCI)=7.4), lower total healthcare costs ($10,083), and 78% patients seeing an oncologist; relative to MITO group (n=143) with 70 years of age, 16% hospital admissions, CCI of 7.5, total healthcare costs of $12,074, and 80% seeing an oncologist. The combo group (n=52) was 66 years old, with 19% hospital admissions, CCI of 8, total healthcare costs of $20, 505, and 92% seeing an oncologist. Median time to MITO from the start of 1L docetaxel was 184 days, 309 days to RECH and 223 days to combo therapy. Midwest (36%) and West (37%) were more frequently using MITO than Northeast (26%) and South (31%), while RECH was more frequently used in Northeast. Conclusions: Patients with mPC in US were most frequently treated with MITO or RECH as 2L chemotherapy after 1L docetaxel. MITO was also given sooner than RECH, hence a valid comparator for comparative effectiveness evaluation on new 2L therapy. Rechallenge with docetaxel increased with time and was given to patients with lower disease burden and healthcare costs than the MITO or Combo group.

Download Full-text

Racial and age specific differences in localized and metastatic prostate cancer incidence: 1988-2013.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.6_suppl.211 ◽

2017 ◽

Vol 35 (6_suppl) ◽

pp. 211-211

Author(s):

Marc Dall'Era ◽

Ralph deVere White ◽

Danielle Rodgriguez ◽

Rosemary Donaldson Cress

Keyword(s):

Prostate Cancer ◽

Cancer Incidence ◽

Metastatic Prostate Cancer ◽

Prostate Cancer Screening ◽

The United States ◽

Incidence Rates ◽

Localized Prostate Cancer ◽

Prostate Cancer Incidence ◽

Race Ethnicity ◽

The Impact

211 Background: The United States Preventive Services Task Force (USPSTF) recommended against routine PSA based prostate cancer screening in all men in 2012. This led to dramatic reductions in screening and rates of localized disease across all clinical risk groups. We sought to study the impact of this on rates of metastatic disease, specifically by patient race and age. Methods: We analyzed new prostate cancer incidence by stage at diagnosis between 1988-2013 within the Cancer Registry of Greater California. We further stratified cases by four major race/ethnicity groups (non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic and non-Hispanic Asian/PI (API)) and age. Incidence rates were calculated and compared per 100,000 and age-adjusted to the 2000 US Standard Population. Joinpoint regression was used to detect changes in incidence and to calculate the average percent change (APC). Results: Adjusted rates of remote prostate cancer incidence for NHW men increased slightly in the most recent decade (+0.28%) after steady declines in previous years with the inflection point occurring in 2002, however this was not statistically significant. In contrast, incidence of remote prostate cancer continued to decline for NHB (-2.73%), Hispanic (-2.04%), and API (-1.45%) men. The greatest increase of +1.1% a year since 2002 was observed for NHW men under age 65. The incidence of localized prostate cancer declined for all race/ethnicity groups over the most recent time period and also declined in all age groups. After remaining relatively flat since 1992, incidence of localized prostate cancer among NHW men declined by over 8% per year starting in 2007 compared with a more gradual decline of -3.52% a year since 2000 for NHB, and more recent declines of -14.41% and -16.64% for Hispanic and API men, respectively. Incidence of regional stage cancer also declined in all groups, but less dramatically. Conclusions: Incidence rates of newly metastatic prostate cancer have not significantly changed since PSA screening declined in the US although we noted a slight upward trend primarily for younger, white men since 2002.

Download Full-text

PD03-07 THE IMPACT OF SOCIOECONOMIC STATUS, RACE, AND INSURANCE TYPE ON THE RISK OF NEWLY DIAGNOSED METASTATIC PROSTATE CANCER IN THE UNITED STATES

The Journal of Urology ◽

10.1016/j.juro.2017.02.213 ◽

2017 ◽

Vol 197 (4S) ◽

Author(s):

Adam Weiner ◽

Richard Matulewicz ◽

Jeffrey Tosoian ◽

Joseph Feinglass ◽

Edward Schaeffer

Keyword(s):

Prostate Cancer ◽

United States ◽

Socioeconomic Status ◽

Metastatic Prostate Cancer ◽

The United States ◽

Newly Diagnosed ◽

Insurance Type ◽

The Impact

Download Full-text

Design and Simulation of Robotic Needle Guide for Transperineal Prostate Biopsy

2018 Design of Medical Devices Conference ◽

10.1115/dmd2018-6867 ◽

2018 ◽

Author(s):

Hossein Dehghani ◽

Shihao Zhang ◽

Pankaj Kulkarni ◽

Pradipta Biswas ◽

Leslie Simms ◽

...

Keyword(s):

Prostate Cancer ◽

United States ◽

Prostate Biopsy ◽

The United States ◽

The Third ◽

Transperineal Prostate Biopsy ◽

The Us ◽

Reproductive Gland

Prostate cancer is the third leading cause of cancer-related death for males in the United States [1]. Over three million Americans with prostate cancer were reported in 2016 [2] marking the prostate cancer as the most prevalent cancer among males in the US. In 2016, 180,890 new cases and 26,120 deaths were reported [1]. The prostate is a male reproductive gland located in the pelvis and surrounded by the rectum posteriorly and the bladder superiorly.

Download Full-text

Patterns of second-line chemotherapy for metastatic prostate cancer in the United States.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e15193 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e15193-e15193

Author(s):

Hongwei Wang ◽

Laura Liao ◽

Eliot Obi-Tabot ◽

Robert Sands ◽

Mathieu Rose ◽

...

Keyword(s):

Prostate Cancer ◽

Healthcare Costs ◽

Metastatic Prostate Cancer ◽

Hospital Admissions ◽

Treatment Options ◽

Patient Characteristics ◽

The United States ◽

Geographic Region ◽

Second Line ◽

Comorbidity Burden

e15193 Background: Patients with prostate cancer progressing from first-line (1L) docetaxel have limited approved treatment options available. Study is to evaluate patterns of second-line (2L) chemotherapy in a US managed care between 2004 and 2010. Methods: Patients with metastatic prostate cancer (mPC) and treated with docetaxel as 1L chemotherapy after July 1, 2004 were ascertained from the OptumInsight database. We evaluated type and timing of chemotherapy and relationships between patient characteristics, physician specialty, healthcare costs and geographic region, 6 months prior to 1L docetaxel and choice of 2L chemotherapy. Results: Patients (N=1,173) were on average 71 yrs old at onset of 1L docetaxel. During a mean follow-up period of 18 months, 38% of patients received 2L treatment. Out of the patients received 2L therapy, 32% received mitoxantrone (MITO), 24% with docetaxel rechallenge (RECH), 14% carboplatin (CARB), and 12% paclitaxel (PAC), plus 11% on Combo therapy. Examination of the 2L treatment groups showed that during the 6 months prior to 1L docetaxel, the RECH group (n=101) was older (73yrs), had fewer hospital admissions (12%), lower comorbidity burden [Charlson Comorbidity Index (CCI)=7.4], lower total healthcare costs ($10,083), and 78% seeing an oncologist; relative to MITO group (n=143) with 70 yrs, 16% hospital admissions, CCI of 7.5, total healthcare costs of $12,074, and 80% seeing an oncologist. The combo group (n=52) was 66 years old, with 19% hospital admissions, CCI of 8, total healthcare costs of $20,505, and 92% seeing an oncologist. Median time to MITO from the start of 1L docetaxel was 184 days, 309 days to RECH and 223 days to Combo therapy. Midwest (36%) and West (37%) were more frequently using MITO than Northeast (26%) and South (31%), while RECH was more frequently used in Northeast. Conclusions: Patients with mPC in US were most frequently treated with MITO or RECH as 2L chemotherapy after 1L docetaxel. MITO was also given sooner than RECH, hence a valid comparator for comparative effectiveness evaluation on new 2L therapy. Rechallenge with docetaxel increased with time and was given to patients with lower disease burden and healthcare costs than the MITO or Combo group.

Download Full-text

Bisphosphonates Treatment in Metastatic Prostate Cancer

European Journal of Inflammation ◽

10.1177/1721727x0500300201 ◽

2005 ◽

Vol 3 (2) ◽

pp. 49-54

Author(s):

F. Berardinelli ◽

M. Iannucci ◽

V. Verratti ◽

W. Fusco ◽

M. Nicolai ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Pain ◽

Metastatic Prostate Cancer ◽

Common Site ◽

The Third ◽

Clinical Complications ◽

Therapeutic Choice ◽

Skeletal Related Events ◽

Skeletal Integrity ◽

Tumor Drugs

The skeleton is the third most common site for cancer to spread after the liver and lungs. Malignancies that can cause destruction of skeletal bones include multiple myeloma and metastatic diseases of the lung, prostate and other solid cancers. The clinical complications include pain, fractures, compression of the spinal cord and hypercalcemia of malignancy. Bisphosphonates are bone-seeking agents originally designed to treat loss of bone density. Accumulating data show that they are effective in diseases in which there is upregulation of osteoclastic or osteolytic activity. Bisphosphonates can reduce skeletal-related events and bone pain, as well as reduce the adverse effects of androgen deprivation therapy on skeletal integrity. However, it is clear that bisphosphonates do not represent a decisive treatment in the care of metastases but a therapeutic choice in synergy with regular anti-tumor drugs. The preclinical and clinical data to support this are reviewed here.

Download Full-text